The objectives of the study are to evaluate the safety and pharmacokinetics of 8-cyclopentyl-1, 3-dipropylxanthine (CPX) in adult patients with mild cystic fibrosis. CPX acts in vitro to correct the cellular metabolism of the most common mutation of cystic fibrosis, namely Df508, to allow proper translocation and membrane function. This is a randomized, double-blind, placebo controlled ascending dose study of orally adminstered CPX in CF adults. Besides safety and pharmacokinetic data, we will also measure biological surrogate markers of efficacy, namely effect on sweat chloride levels and nasal transepithelial potential difference measurements.
Showing the most recent 10 out of 589 publications